EUVIMEDObjevte EUVIMED
Crossref

Exploring the Effect of Gomisin A on Non‐Small Cell Lung Cancer With Network Pharmacology, Molecular Docking, In Vitro and In Vivo Assays

Mei Liu, Kai Yang, Huibing Qiu

Chemical Biology & Drug Design · 2024

DOI: 10.1111/cbdd.70014 ↗

At a glance

Journal article in Chemical Biology & Drug Design, 2024. Written by Mei Liu and 2 co-authors. Institution: Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China. Major MEDLINE topics: Carcinoma, Non-Small-Cell Lung, Molecular Docking Simulation, Lung Neoplasms, Lignans. 53 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Gomisin A is an active ingredient of Schisandra chinensis . Pre‐clinical studies suggest Gomisin A has good anti‐cancer activities against a variety of cancers, but its mechanism of action in non‐small cell lung cancer (NSCLC) is unclear. This study aims to explore the potential mechanism of Gomisin A in treating NSCLC. The SwissTargetPrediction, CTD, HERB and PharmMapper databases were used to collect related targets of Gomisin A. NSCLC‐related genes were obtained using the GEO, CTD, DisGeNET, OMIM, GeneCards, NCBI, and PharmGKB databases. The central targets and potential mechanisms of Gomisin A against NSCLC were screened using network pharmacology and molecular docking. Finally, the therapeutic activity of Gomisin A on NSCLC was verified by experiments. A total of 161 potential targets of Gomisin A against NSCLC were identified. TNF, AKT1, STAT3, and IL6 were identified as the central targets of Gomisin A. The binding energy of Gomisin A and the central targets was less than −5 kcal/mol. Gomisin A could inhibit NSCLC cell viability, migration and invasion and induce cell cycle arrest and apoptosis. Gomisin A also inhibited in vivo metastasis of NSCLC cells. In addition, Gomisin A could also reduce the expression level of the central targets and inhibit the PI3K‐Akt signaling pathway. In summary, Gomisin A may be a candidate drug for the treatment of NSCLC, and TNF, AKT1, STAT3, and IL6 are potential targets for Gomisin A in NSCLC treatment, and its therapeutic mechanism may be related to the PI3K‐Akt signaling pathway.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Non-Small-Cell LungMolecular Docking SimulationLung NeoplasmsLignansHumansAnimalsCell Line, TumorMiceCell ProliferationApoptosisNetwork PharmacologySignal TransductionCyclooctanesCell MovementSchisandraMice, NudeProto-Oncogene Proteins c-aktPolycyclic CompoundsPhosphatidylinositol 3-KinasesA549 Cells

Author keywords

Gomisin Amolecular dockingnetwork pharmacologynon‐small cell lung cancer

Substances

LignansCyclooctanesProto-Oncogene Proteins c-aktPolycyclic CompoundsPhosphatidylinositol 3-Kinases

Authors and institutions

  • Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China.

Cite

APA

Liu, M., Yang, K., & Qiu, H. (2024). Exploring the Effect of Gomisin A on Non‐Small Cell Lung Cancer With Network Pharmacology, Molecular Docking, In Vitro and In Vivo Assays. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70014

Vancouver

Liu M, Yang K, Qiu H. Exploring the Effect of Gomisin A on Non‐Small Cell Lung Cancer With Network Pharmacology, Molecular Docking, In Vitro and In Vivo Assays. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.70014

BibTeX
@article{Liu2024,
  author = {Liu, Mei and Yang, Kai and Qiu, Huibing},
  title = {Exploring the Effect of Gomisin A on Non‐Small Cell Lung Cancer With Network Pharmacology, Molecular Docking, In Vitro and In Vivo Assays},
  journal = {Chemical Biology & Drug Design},
  year = {2024},
  doi = {10.1111/cbdd.70014}
}
Start for free →